scholarly journals Inpatient management and post-discharge outcomes of hyperkalemia

2021 ◽  
pp. 1-7
Author(s):  
Jill Davis ◽  
Rubeen Israni ◽  
Fan Mu ◽  
Erin E. Cook ◽  
Harold Szerlip ◽  
...  
Author(s):  
Marat Fudim ◽  
Toi Spates ◽  
Jie-Lena Sun ◽  
Veraprapas Kittipibul ◽  
Jeffrey M. Testani ◽  
...  

2016 ◽  
Vol 44 (12) ◽  
pp. 346-346
Author(s):  
Carmela Socolovsky ◽  
Ryan Cauley ◽  
Clare Horkan ◽  
Kenneth Christopher

2019 ◽  
Vol 218 (2) ◽  
pp. 342-348 ◽  
Author(s):  
David A. Mahvi ◽  
Linda M. Pak ◽  
Richard D. Urman ◽  
Jason S. Gold ◽  
Edward E. Whang

2019 ◽  
Vol 278 ◽  
pp. 28-33 ◽  
Author(s):  
Hoang Tran ◽  
Nancy Byatt ◽  
Nathaniel Erskine ◽  
Darleen Lessard ◽  
Randolph S. Devereaux ◽  
...  

Author(s):  
Caitlin Fette ◽  
Rachel Krallman ◽  
Colin McMahon ◽  
Daniel Montgomery ◽  
Jennifer Wang ◽  
...  

Background: Prior studies have shown that patients with diabetes mellitus (DM) have increased risk for developing cardiovascular disease. BRIdging the Discharge Gap Effectively (BRIDGE) is a nurse practitioner-delivered cardiac transitional care program for patients who have been recently discharged following a cardiac event. Previous research has shown BRIDGE to be effective in improving patient outcomes. This study sought to describe differences in outcomes 1) of heart failure (HF), acute coronary syndrome (ACS), and atrial fibrillation (AF) patients with and without concomitant DM, and 2) between diabetic patients who did and did not attend BRIDGE. Methods: Retrospective data were abstracted for HF, ACS, and AF patients from 2008-2014. Patients were divided into cohorts based on presence or absence of DM and BRIDGE attendance versus non-attendance. Outcomes (readmissions, ED visits, death) within each primary diagnosis (HF, ACS, AF) were compared between DM and non-DM patients and between those who attended BRIDGE versus those who did not for all DM patients. Results: Of 2197 patients referred to BRIDGE, 723 (32.9%) had concomitant DM. DM patients had similar outcomes to non-DM patients for most post-discharge outcomes; however, DM ACS patients had higher readmission (42.2% v 29.6%, p<0.001) and death (10.5% v. 4.5%, p=0.001) rates within 6 months, and DM AF patients had higher readmission rates within 6 months (52.1% v 37.9%, p=0.006). HF patients with DM who attended BRIDGE had lower mortality rates within 6 months of discharge than those who did not (10.3% vs. 22.1%, p=0.014). No other significant differences in outcomes were seen between BRIDGE attendees and non-attendees. Conclusions: Though not significant, patients with DM had worse post-discharge outcomes than those without DM for all primary diagnoses. In the subset of DM patients, the 30-day readmission rate for ACS patients who attended BRIDGE was half of those who did not attend. Conversely, 30-day readmission rates for HF patients were greater if they attended. This may in part explain the significantly lower mortality rate among BRIDGE attenders with HF, where patients who needed readmission were identified during their BRIDGE appointment. Due to the high prevalence of DM, efforts to tailor transitional care for this population are needed.


2007 ◽  
Vol 13 (6) ◽  
pp. S162-S163
Author(s):  
Nancy M. Albert ◽  
Gregg C. Fonarow ◽  
Christopher M. O'Connor ◽  
Wendy G. Stough ◽  
Eduardo Nunez ◽  
...  

2018 ◽  
Vol 3 (1) ◽  
Author(s):  
Shinya Tanaka ◽  
Kentaro Kamiya ◽  
Nobuaki Hamazaki ◽  
Ryota Matsuzawa ◽  
Kohei Nozaki ◽  
...  

Background A simple and inexpensive sarcopenia screening tool would be beneficial in clinical practice. This study was performed to determine whether SARC-F questionnaire can be used to identify physical limitations and poor prognosis in elderly cardiovascular disease (CVD) patients.Methods The study population consisted of 257 Japanese patients ≥65 years old admitted to our hospital for CVD. Prior to discharge from hospital, SARC-F, handgrip strength, usual gait speed, short physical performance battery score, and 6-minute walking distance were measured in all patients. The patients were divided into two groups according to SARC-F score: SARC-F <4 and SARC-F ≥4. The study endpoint was the first occurrence of all-cause emergency readmission or all-cause mortality.Results The prevalence rate of SARC-F ≥4 was 26.8%, and increased with age and number of comorbidities. Even after adjusting for covariates, physical function was significantly poorer and the risks of physical function measurements below the critical cut-off values were higher in the SARC-F ≥4 group compared to the SARC-F <4 group. Sixty (23.3%) patients were readmitted and 17 (6.6%) died over a median follow-up period of 11 months (interquartile range: 6–13 months). SARC-F score was a significant predictor of adverse events after discharge. Patients with SARC-F ≥4 showed higher event risk than those with SARC-F <4 (adjusted hazard ratio: 1.78; 95% confidence interval: 1.03–3.07; P = 0.040).Conclusions SARC-F questionnaire is useful to identify patients at high risk of physical limitations and to predict post-discharge outcomes in elderly CVD patients.


Sign in / Sign up

Export Citation Format

Share Document